Business
Currency:USD
2024/FY
Stock NameRevenueRatio
Revenue from anti-CD20 therapeutic programs1.75B18.09%
TYSABRI1.72B17.72%
SPINRAZA1.57B16.26%
TECFIDERA967.1M9.99%
Other821M8.48%
AVONEX707.5M7.31%
Contract manufacturing, royalty and other revenue652.6M6.74%
VUMERITY628M6.49%
BENEPALI479.1M4.95%
SKYCLARYS382.5M3.95%
View all
Region
Currency:USD
2024/FY
Stock NameRevenueRatio
U.S.5.31B54.84%
Europe2.17B22.45%
Germany955.6M9.88%
Asia624.1M6.45%
Other557.9M5.77%
Alzheimer's collaboration revenue59.9M0.62%
View all